DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced the award of a multi-million dollar, five-year technology and services agreement with Bellicum Pharmaceuticals.
DATATRAK worked with Bellicum to design a combined technology and services offering to assist in the progression of their oncology products throughout the FDA clinical trial process. As a biotherapeutics company, Bellicum needs to control data collection and management costs for their biological drug products from development through commercialization. The DATATRAK Enterprise pricing model and DATATRAK Clinical and Consulting Services' (DCCS) expertise were the ideal solution for Bellicum. The DATATRAK Enterprise pricing model allowed Bellicum to project their costs over the five year period of clinical trial execution, and with DCCS providing a full suite of professional services, Bellicum enjoys a single source vendor for their data needs.
"We are pleased to collaborate with DATATRAK on our clinical trial programs," said Tom Farrell, CEO of Bellicum. "This partnership will enable us to advance our two lead clinical development programs for patients with prostate cancer and patients undergoing a hematopoietic stem cell transplant."